Spiriva (tiotropium) is a prescription drug used to treat specific breathing conditions. Spiriva’s cost may depend on factors such as your dosage, whether you have health insurance, and the pharmacy ...

Spiriva (tiotropium bromide) is a prescription drug that’s used to treat COPD and asthma. The drug comes in an inhaler. It’s usually used once per day. Spiriva is a prescription drug that comes in two ...

Tiotropium (as bromide monohydrate) 18mcg/cap; dry pwd in caps for oral inhalation; with inhaler device. Spiriva Handihaler consists of Spiriva capsules and the Handihaler device. Spiriva capsules ...

Want to know what asthma feels like? Try a crushing bear hug. That’s what patients told Boehringer Ingelheim, informing its latest campaign for Spiriva Respimat as a treatment for asthma. In new TV ...

Tiotropium (as bromide monohydrate) 1.25mcg, 2.5mcg; per actuation; inh spray; contains benzalkonium chloride. Spiriva Respimat Inhalation Spray is supplied in a carton containing one Spiriva Respimat ...

Lannett has entered into an exclusive U.S. commercialization agreement for generic Spiriva Handihaler (Tiotropium Bromide inhalation powder) with Respirent Pharmaceuticals. The 10-year term of the ...

Lupin has received the Food and Drug Administration’s permission for Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, which is a generic of Boehringer Ingelheim’s Spiriva HandiHaler. The ...

Federal health regulators said Thursday that recent data do not show a connection between a popular inhaler and previously reported risks of stroke, heart attack and death. The Spiriva HandiHaler is ...

BOSTON (Reuters) - Adding Spiriva to conventional therapy improves symptoms in patients whose asthma is poorly controlled and gives them more days without breathing problems, researchers reported on ...

Major League Baseball’s annual All-Star Game last night featured new DTC spots for Spiriva HandiHaler, an inhaler indicated for chronic bronchitis and emphysema. The television spots were created by ...

A Spiriva-based combination therapy that Boehringer Ingelheim believes will consolidate its position in the chronic obstructive pulmonary disease (COPD) market has been cleared for marketing in nine ...

In laying out their respective plans Monday to launch new direct-to-patient (DTP) platforms paring down the prices of popular medicines in the U.S., Novartis and Boehringer Ingelheim are falling in ...